Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor(IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
2 mg | In stock | $ 70.00 | |
5 mg | In stock | $ 139.00 | |
10 mg | In stock | $ 198.00 | |
25 mg | In stock | $ 369.00 | |
50 mg | In stock | $ 549.00 | |
100 mg | In stock | $ 789.00 | |
500 mg | In stock | $ 1,630.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 143.00 |
Description | Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor(IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively). |
Targets&IC50 | PKCα:1.9 nM , PKCθ:0.4 nM , GSK-3β:3.1 μM |
In vitro | An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival. |
Synonyms | LXS196 |
Molecular Weight | 472.47 |
Formula | C22H23F3N8O |
CAS No. | 1874276-76-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (211.65 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Darovasertib 1874276-76-2 Chromatin/Epigenetic Cytoskeletal Signaling PKC LXS196 Protein kinase C IDE196 Inhibitor LXS 196 LXS-196 IDE-196 IDE 196 inhibit inhibitor